https://9690d.iqanda-cme.com/ 2019-06-06T22:58:28+0000 weekly 1 https://9690d.iqanda-cme.com/about-iqanda-diabetes-management 2019-04-08T22:35:40+0000 weekly 0.8 https://9690d.iqanda-cme.com/diabetes-management 2019-09-07T01:26:09+0000 weekly 0.8 https://9690d.iqanda-cme.com/submit-a-question 2019-05-08T18:51:57+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/as-a-leading-authority-in-ldl-c-mediated-cv-risk-reduction-can-you-provide-us-with-your-perspective-on-the-evidence-for-pcsk9-inhibitors-as-a-foundational-approach-for-managing-a-broad-spectrum-of-patients-with-high-risk-coronary-heart-d 2019-04-02T01:11:20+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/which-patients-in-your-view-are-not-candidates-for-pcsk9-inhibition 2019-04-08T04:55:18+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/when-is-70-mg/dl-not-good-enough-is-this-a-threshold-what-clinical-factors-suggest-lower-targets-are-better-what-is-happening-at-the-vascular-biology-level 2019-04-02T01:11:27+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/in-the-lipid-clinic-setting-in-patients-you-have-treated-with-pcsk9-inhibitors-what-are-you-finding-as-far-as-regimen-adherence-toleration-and-patient-engagement/satisfaction-with-these-injectable-strategies 2019-04-08T04:53:49+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/do-you-see-safety-signals-associated-with-ultra-aggressive-ldl-c-lowering-and-what-is-the-role-of-pad-as-a-risk-factor-guiding-ldl-c-reduction 2019-04-02T01:11:36+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/as-the-director-of-the-center-for-cardiovascular-disease-prevention-what-patient-types-on-the-risk-landscape-of-ascvd-do-you-believe-deserve-special-attention-because-they-are-likely-to-be-eligible-candidates-for-pcsk9-mediated-ldl-c-red 2019-04-02T01:11:21+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/in-the-setting-of-secondary-prevention-for-patients-with-diabetes-the-role-of-ldl-c-has-special-significance-how-do-you-view-the-importance-for-the-of-pcsk9-inhibitors-therefore-specifically-for-reducing-residual-cv-risk-in-the-t2d-popul 2019-04-02T01:11:34+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/what-did-we-learn-specifically-about-the-population-of-patients-with-post-acs-and-t2d-who-were-treated-with-alirocumab-in-the-odyssey-outcomes-trial 2019-04-08T04:57:57+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/how-should-the-lipid-specialist-approach-the-individual-with-diabetes-who-doesn-t-yet-have-ascvd 2019-04-08T04:53:06+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/you-have-identified-the-challenges-of-accessing-pcsk9-inhibitors-for-patients-whose-cv-risk-is-genetic-vs-those-whose-clinical-course-is-characterized-by-progressive-vascular-events-how-do-you-approach-each-subset-with-respect-to-ldl-c-m 2019-04-02T01:11:23+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/what-is-the-profile-of-the-diabetic-patient-in-whom-the-diabetes-specialist-should-strongly-consider-the-ldl-c-lowering-and-outcome-improving-effects-of-pcsk9-inhibitors-how-do-we-risk-stratify-populations-for-secondary-prevention 2019-04-02T01:12:03+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/which-diabetic-patients-in-particular-should-be-prioritized-for-pcsk9-mediated-cv-risk-reduction 2019-04-02T01:11:32+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/what-are-the-principal-concerns-related-to-cv-risk-reduction-in-patients-with-t2d-and-where-does-ldl-c-lowering-with-pcsk9-inhibitors-fit-into-the-clinical-strategy 2019-04-02T01:11:29+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/what-is-your-analysis-of-the-two-major-cv-outcome-trials-and-from-a-mortality-end-point-perspective-in-what-way-do-mortality-outcome-end-points/results-distinguish-the-odyssey-outcomes-trial-with-alirocumab 2019-04-08T04:57:15+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/from-the-perspective-of-a-lipid-medicine-specialist-how-do-the-results-of-the-now-published-odyssey-outcomes-trial-and-related-trials-help-you-select-patients-for-pcsk9-mediated-ldl-c-reduction-and-what-targets-do-you-advocate 2019-04-08T04:52:20+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/given-that-odyssey-outcomes-has-shown-not-only-reduction-in-cv-events-but-also-a-reduction-in-associated-all-cause-mortality-what-is-the-role-of-pcsk9-inhibitors-in-diabetes-patients-with-a-prior-acs-event 2019-04-02T01:11:35+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/you-have-made-the-case-for-a-call-to-action-to-treat-ldl-c-very-aggressively-in-diabetic-patients-with-known-ascvd-what-is-your-rationale-for-this-and-how-do-the-recent-rials-support-your-recommendation-to-treat-diabetics-with-ascvd-aggr 2019-04-08T04:50:56+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/what-are-the-specific-patient-types-that-you-manage-in-your-lipid-focused-practice-and-which-are-referred-to-you-for-potential-intervention-with-a-pcsk9-inhibitor-why-are-these-patients-being-referred-to-you-for-pcsk9-mediated-ldl-c-redu 2019-04-08T04:54:30+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/can-you-paint-the-profile-of-the-post-acs-patient-with-t2d-in-whom-the-aggregate-cv-risk-exceeds-a-threshold-that-supports-a-strategy-of-pcsk9-mediated-ldl-c-reduction-in-order-to-achieve-levels-of-less-than-70-mg/dl-or-even-less-than-50 2019-04-02T01:11:28+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/based-on-odyssey-outcomes-for-which-biological/metabolic-risk-markers-do-you-feel-that-cardiologists-and-atherosclerosis-specialists-should-strive-to-achieve-ldl-c-levels-even-more-aggressive-than-those-identified-in-the-aha-guidelines 2019-04-02T01:11:22+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/why-are-patients-who-should-clearly-be-on-a-pcsk9-inhibitor-not-being-treated-in-the-primary-cardiology-setting-but-rather-seeking-and-obtaining-this-treatment-in-the-lipid-clinic-environment 2019-04-02T01:11:24+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/in-the-type-2-diabetes-population-that-you-manage-in-your-what-percentage-of-patients-do-you-estimate-do-not-achieve-risk-appropriate-ldl-c-for-any-number-of-reasons-is-it-as-high-as-10-as-reported-in-by-some-diabetes-experts 2019-04-02T01:11:33+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/what-is-the-rationale-for-a-new-category-called-extreme-risk-introduced-by-aace-in-which-they-designate-a-threshold-ldl-c-target-of-55-mg/dl 2019-04-08T04:56:30+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/how-large-is-the-subgroup-of-diabetic-patients-who-you-feel-are-likely-to-appropriate-candidates-for-pcsk9-inhibition-to-optimize-cv-risk-reduction-and-how-does-the-lack-of-a-safety-signal-influence-your-recommendations-for-this-group 2019-04-02T01:12:05+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/to-what-degree-have-you-observed-statin-intolerance-or-resistance-in-patients-with-high-risk-cad-what-protocol-do-you-employ-to-mitigate-and/or-manage-statin-intolerance-where-does-the-pcsk9-inhibitor-fit-into-your-sequencing-strategy 2019-04-02T01:12:07+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/from-a-lipid-specialist-perspective-how-do-you-navigate-the-risk-territory-of-ldl-c-levels-70-mg/dl-with-pcsk9-inhibitors-and-in-which-patient-subgroups-do-these-agents-offer-unique-outcome-related-benefits 2019-04-08T04:51:35+0000 weekly 0.8 https://9690d.iqanda-cme.com/videos/what-is-the-unmet-need-for-residual-cv-risk-reduction-in-post-acs-patients-with-t2d-in-your-role-as-a-member-of-the-ldl-guideline-group-for-aace-what-were-the-implications-of-treating-diabetic-patients-with-so-called-extreme-risk 2019-04-08T04:50:23+0000 weekly 0.8 https://9690d.iqanda-cme.com/courses/from-landmark-cv-outcome-trials-to-the-front-lines-of-ascvd-risk-reduction 2023-04-14T03:36:31+0000 weekly 0.8 https://9690d.iqanda-cme.com/flexpaper/program-agenda-part-4-and-complete-faq-list 2019-03-30T00:37:40+0000 weekly 0.8 https://9690d.iqanda-cme.com/flexpaper/applicability-and-cost-implications-for-pcsk9-inhibitors-based-on-the-odyssey-outcomes-trial 2019-03-28T01:09:56+0000 weekly 0.8 https://9690d.iqanda-cme.com/flexpaper/program-agenda-and-complete-faq-list1 2019-04-02T17:15:41+0000 weekly 0.8 https://9690d.iqanda-cme.com/flexpaper/infographic-nla-expert-panel-pcsk9-recommendations 2019-03-28T01:08:59+0000 weekly 0.8 https://9690d.iqanda-cme.com/flexpaper/2016-esc/eas-guidelines-for-the-management-of-dyslipidaemias 2019-03-28T01:10:09+0000 weekly 0.8 https://9690d.iqanda-cme.com/flexpaper/nla-expert-panel-pcsk9-recommendations 2019-03-28T01:09:25+0000 weekly 0.8 https://9690d.iqanda-cme.com/flexpaper/2018-aha/acc-guideline-on-the-management-of-blood-cholesterol 2019-03-28T01:10:21+0000 weekly 0.8 https://9690d.iqanda-cme.com/flexpaper/pooled-analysis-of-10-odyssey-trials-comparing-reductions-in-atherogenic-lipids-and-major-cv-events 2019-03-28T01:09:41+0000 weekly 0.8 https://9690d.iqanda-cme.com/flexpaper/program-agenda-and-complete-faq-list 2019-03-28T01:09:12+0000 weekly 0.8 https://9690d.iqanda-cme.com/flexpaper/the-odyssey-outcomes-trial-topline-results-alirocumab-in-patients-after-acute-coronary-syndrome 2019-03-28T01:10:38+0000 weekly 0.8